Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.10 (6.25%)
Bid:
1.55
Ask:
1.85
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Wideacademy Restructuring

30 Oct 2018 07:00

RNS Number : 5970F
WideCells Group PLC
30 October 2018
 

30 October 2018

WideCells Group PLC ('WideCells Group' or 'the Group')

 

Board Restructuring and Cost Cutting

 

WideCells Group PLC, the healthcare services group focused on providing stem cell services and insurance for stem cell treatment, has undertaken further corporate restructuring and cost cutting measures to rationalise its Board and to refocus on its core operational divisions.

 

As part of this restructuring, Alan Greenberg has resigned from his positions as a Director of the Board and Chief Business Development Officer and Senior Vice President of Wideacademy.

 

In addition, the Company has closed Wideacademy's London office and has brought the division into the Manchester head office, thereby making annualised savings of approximately £400,000 pa.

 

Wideacademy will continue to use its current collaborations with the education and medical sectors, and will harness Professor Peter Holland's knowledge in stem cell education and training to bolster the Group's stem cell storage and insurance sales.

 

The Group's CEO, João Andrade, said, "I'd like to thank Alan Greenberg for his dedication to WideCells and I wish him all the best for the future. The streamlined Board and Wideacademy is now fully focused on increasing sales at our two core divisions - CellPlan, the world's first stem cell healthcare insurance plan; and WideCells, focused on stem cell storage and, research, in order to generate value for our shareholders."

 

**ENDS**

 

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 

WideCells Group

CEO - João Andrade

Tel: +44 (0)161 920 7953

Shard Capital Partners LLP

Broker - Damon Heath & Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR - Isabel de Salis & Priit Piip

Tel: +44 (0) 20 7236 1177

 

Notes to Editors

 

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments both accessible and affordable. This is delivered through three divisions:

· CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

· WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

· Wideacademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

 

Stem Cell Fast Facts:

· Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families, because it is simple, safe and painless to collect, relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.

· Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

· 82 illnesses can currently be treated using stem cell procedures.

· Despite initial collection and storage often costing no more than a few £thousands, actual treatment can cost in the £hundreds of thousands - before the development of an insurance product such as CellPlan, the treatment remained largely available only to Higher Net Worth individuals.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOADXBDGCGDBGIC
Date   Source Headline
2nd Jun 20265:18 pmRNSConversion of Notes and Allotment of Shares
29th May 20267:00 amRNSTotal Voting Rights
29th Apr 202612:58 pmRNSConversion of Notes and Allotment of Shares
31st Mar 20267:00 amRNSInterim Results
27th Feb 202610:23 amRNSTotal Voting Rights
23rd Feb 20267:00 amRNSConversion of Notes and Allotment of Shares
31st Dec 202511:37 amRNSResult of AGM
8th Dec 20252:16 pmRNSNotice of AGM
23rd Oct 20252:30 pmRNSFull Year Results
12th Aug 20252:04 pmRNSUpdate on Compliance with UK Listing Rules
30th Jun 20253:27 pmRNSHolding(s) in Company
30th Jun 20253:25 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSTotal Voting Rights
9th Jun 20254:28 pmRNSConversion of Notes and Allotment of Shares
6th Jun 20259:48 amRNSConversion of Notes and Allotment of Shares
3rd Jun 20252:54 pmRNSConversion of Notes and Allotment of Shares
30th May 20254:00 pmRNSConversion of Notes and Allotment of Shares
28th May 20255:24 pmRNSConversion of Notes and Allotment of Shares
28th May 20254:54 pmRNSHolding(s) in Company
28th May 20254:52 pmRNSHolding(s) in Company
28th May 20254:50 pmRNSHolding(s) in Company
28th May 20254:48 pmRNSHolding(s) in Company
20th May 20257:30 amRNSRestoration Iconic Labs Plc
20th May 20257:00 amRNSRestoration of Trading and Funding Update
15th May 20254:18 pmRNSResult of AGM
24th Apr 20255:16 pmRNSNotice of AGM
31st Mar 20256:41 pmRNSInterim Results
31st Mar 20255:26 pmRNSRevised Results for the Year ended 30 June 2024
13th Feb 20255:55 pmRNSTransaction Terminated
7th Feb 20252:52 pmRNSNotification of Major Holdings
31st Oct 20243:57 pmRNSFull Year Results for the Year ended 30 June 2024
9th Sep 20247:00 amRNSWaiver of Event of Default
10th Jul 20244:22 pmRNSBoard Changes
28th Mar 20247:00 amRNSInterim Results
11th Mar 202412:00 pmRNSHeads of Terms Signed
29th Feb 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSSuspension of Trading
13th Feb 20242:08 pmRNSResult of AGM
7th Feb 20249:10 amRNSConversion of Notes and Allotment of Shares
19th Jan 20243:49 pmRNSNotice of AGM
4th Jan 20247:00 amRNSBoard Changes & Business and Strategy Update
29th Dec 20237:00 amRNSTotal Voting Rights
7th Dec 20238:53 amRNSConversion of Securities
4th Dec 20237:53 amRNSConversion of Securities
30th Nov 20237:00 amRNSTotal Voting Rights
17th Nov 202311:32 amRNSConversion of Securities
13th Nov 20238:40 amRNSConversion of Securities
2nd Nov 202310:35 amRNSConversion of Securities
31st Oct 20239:29 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSFull Year Results for the Year ended 30 June 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.